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Purpose: Carbonic anhydrase is elevated in the vitreous of patients with proliferative diabetic retinopathy (PDR). This
study aimed to determine if common polymorphisms in the carbonic anhydrase (CA) gene influence susceptibility to
diabetic retinopathy (DR).
Methods: In this multicentered study, a total of 235 control subjects with no DR, 158 subjects with nonproliferative DR
(NPDR), 132 with proliferative DR (PDR), and 93 with clinically significant macular edema (CSME) were recruited.
Blinding DR was defined as severe NPDR, PDR or CSME. DR subjects were drawn from both type 1 diabetes mellitus
(T1DM) and type 2 diabetes mellitus (T2DM) populations. Ten tag single nucleotide polymorphisms were selected to
cover the majority of genetic diversity across the CA gene.
Results: After adjustments were made for sex, disease duration, and HbA1c, no associations were found between any CA
polymorphisms or haplotypes with any type of retinopathy in T1DM or T2DM.
Conclusions: Sequence variation in CA is not associated with the risk of developing retinopathy in T1DM or T2DM and
increases the likelihood that elevated vitreous CA may be a consequence rather than cause of DR. Further genetic studies
are required to have a better understanding of the pathogenesis of this debilitating diabetic complication.
Diabetic  retinopathy  (DR)  is  a  sight-threatening
microvascular complication of diabetes mellitus (DM) and a
major cause of morbidity in individuals with diabetes. With
global incidence of DM predicted to double over the next two
decades [1], consequent DR frequency has also been predicted
to rise [2,3].
There are several well established risk factors for DR,
namely  hyperglycemia,  diabetes  duration,  and  systemic
hypertension  [4-10].  There  is  also  increasing  evidence
supporting a genetic component in DR susceptibility given the
heterogeneity of DR in subjects with equally poor glycemic
control. Several studies, including the Diabetes Control and
Complications Trial, have provided evidence for a familial
tendency toward DR development, independent of associated
risk factors [11-14].
Vitreous humor from PDR patients has been found to
contain up to 50 different proteins [15,16], with several studies
reporting higher levels of vascular endothelial growth factor
and  erythropoietin  in  PDR  vitreous  when  compared  to
vitreous of nondiabetic patients [17-19]. Carbonic anhydrase
(CA) is a widely expressed enzyme in humans that catalyzes
the conversion of carbon dioxide to bicarbonate and protons.
It thereby plays an important role in acid-base balance [20]
and has also been isolated in the human retina [21,22]. Gao et
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al. [23] recently undertook a proteomic analysis of vitreous
from  individuals  with  diabetes  and  found  the  CA
concentration  in  individuals  with  proliferative  diabetic
retinopathy (PDR) patients to be significantly higher than in
control participants without DM or individuals with DM but
without DR. In support of a pathological role for CA in DR,
intravitreal injection of CA in rats induced retinal fluorescein
leakage and retinal edema that was inhibited by coinjection of
acetazolamide  (a  specific  CA  inhibitor).  Intravitreal  CA
injection  increased  retinal  vascular  permeability  through
increasing vitreous pH, leading to activation of the kallikrein-
kinin system. Thus, the CA pathway is potentially important
in the development of DR (and especially macular edema),
which  is  characterized  in  part  by  increased  vascular
permeability and retinal edema.
Given the evidence indicating a potential role of CA in
DR pathogenesis, the aim of this study was to determine if
common polymorphisms in the CA gene might contribute to
DR susceptibility, for example by influencing CA expression
levels or enzyme activity. To our knowledge, this is the first
study to examine this potential association.
METHODS
Patients with DR were recruited from the ophthalmology and
endocrine clinics of three tertiary hospitals in metropolitan
Adelaide, Australia. Ethics approval was obtained from the
Human Research Ethics Committees of each hospital, and
written informed consent was received from each participant.
Enrolled were 554 individuals with DM: 190 with type 1
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1179(T1DM) and 364 with type 2 diabetes mellitus (T2DM) of
Caucasian European descent. All participants were over 18
years of age and were required to have either T1DM or T2DM
of at least 5 years duration, necessitating oral hypoglycemic
or insulin treatment.
Retinopathy status was graded according to the Early
Treatment  Diabetic  Retinopathy  Study  criteria  [24],  and
retinopathy status for the worst eye was used in the analyses.
Blinding DR was classified as severe nonproliferative DR
(NPDR),  PDR  or  clinically  significant  macular  edema
(CSME). A detailed questionnaire was conducted, obtaining
information regarding ethnicity, diabetes related risk factors
and systemic and ocular complications. Blood pressure and
body mass index (BMI) were measured. Renal function tests
(serum  creatinine,  urine  albumin,  and  albumin:creatinine
ratio), blood cholesterol, and HbA1c levels were obtained.
Three recent HbA1c levels were averaged for each participant.
For those cases diagnosed with blinding DR, HbA1c levels at
the time of the ocular complication were used, and for no
retinopathy  controls  with  DM,  HbA1c  levels  immediately
before recruitment were averaged. Patients were classified as
hypertensive if they were on treatment for hypertension or if
they had a blood pressure reading greater than or equal to
140/90  mmHg  at  the  time  of  recruitment.
Hypercholesterolemia was defined as a total cholesterol equal
to or greater than 5.5 mmol/l, or current use of lipid lowering
medication.  Nephropathy  was  defined  as  the  presence  of
microalbuminuria  (30–300  mg/day)  or  macroalbuminuria
(>300 mg/day). DNA was extracted from peripheral blood
samples  using  the  QiaAmp  Blood  Maxi  Kit  (Qiagen,
Valencia, CA).
Using the tagger program implemented in Haploview 4.0
[25] tag single nucleotide polymorphisms (SNPs) across the
CA gene, including the promoter region were selected. SNPs
were selected on the basis of linkage disequilibrium patterns
observed  in  the  Caucasian  (CEU)  samples  that  were
genotyped  as  a  part  of  the  International  HapMap  Project
[26]. Only SNPs with minor allele frequency greater than 5%
in HapMap were considered. Ten tag SNPs which captured
all alleles with an r2 of at least 0.8 (mean r2=0.963), were
genotyped in all individuals using iPLEX Gold chemistry on
an autoflex Mass Spectrometer (Sequenom, San Diego, CA).
SNP genotyping was checked for compliance with the
Hardy–Weinberg  equilibrium  using  a  χ2  test.  Genotypic
associations were assessed in SNPstats [27]. Dominant and
recessive models were considered with respect to the minor
allele. Haplotypic associations were undertaken in HaploStats
(version 1.2.1) [28]. The study was designed to have at least
80% power to detect SNP associations with odds ratios of
approximately 1.5, assuming a disease prevalence of 60%
among individuals with diabetes, a marker allele frequency of
0.15, and moderate LD between the marker and disease locus.
RESULTS
Of  the  554  participants  recruited  for  this  study,  281
participants had no DR and 273 had DR. Of the participants
with DR, the grading for the worse affected eye was used in
the analyses, with a hierarchy PDR considered worse than
NPDR.  CSME  was  also  considered  separately  as  an
independent analysis. There were 215 participants classified
as having blinding DR: 23 participants with severe NPDR,
132 with PDR, and 93 with CSME. Some individuals fell into
more than one group of DR as CSME can jointly occur with
any  of  the  other  DR  gradings.  If  either  eye  had  CSME
irrespective of other DR gradings, the patient was classified
as having CSME.
Subjects with T1DM and no DR had a significantly lower
age, shorter disease duration, lower HbA1c, lower rates of
nephropathy and hypertension compared to the T1DM cases
with  blinding  DR.  Patients  with  T2DM  and  no  DR  were
significantly more likely to be female and have shorter disease
duration, lower HbA1c levels, lower BMI readings and lower
rates  of  nephropathy  when  compared  to  participants  with
T2DM and blinding DR (Table 1).
TABLE 1. COMPARISON OF CLINICAL CHARACTERISTICS OF PARTICIPANTS BY TYPE OF DIABETES AND DR STATUS.
Clinical characteristics
T1DM T2DM
p value
No DR
(n=94)
Blinding DR
(n=76)
No DR
(n=187)
Blinding DR
(n=139)
Sex (female) 48 (51) 29 (45) 0.478 100 (53) 45 (35) 0.001
Age (years) 38.4±14.9 49.8±15.5 <0.001 64.3±14.5 64.0±10.7 0.853
Disease duration (years) 15.4±9.1 30.9±13.4 <0.001 12.9±8.7 17.5±8.6 <0.001
HbA1c (%) 7.6±2.5 8.8±2.3 0.004 6.6±2.9 7.5±3.4 0.014
BMI (kg/m2) 25.9±7.1 25.9±9.8 0.958 32.2±9.1 29.6±11.5 0.026
Hypercholesterolemia (%) 33 (35) 32 (50) 0.062 120 (64) 81 (63) 0.802
Nephropathy (%) 40 (15) 29 (45) <0.001 43 (23) 46 (36) 0.014
Smoker (%) 44 (47) 35 (55) 0.331 99 (53) 69 (53) 0.924
Hypertension (%) 37 (39) 46 (72) <0.001 153 (82) 107 (83) 0.796
Results are presented as number of subjects (%) or mean±standard deviation. P-values for comparison between cases and controls
are given.
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p valueSNP  analysis:  All  SNPs  were  in  Hardy–Weinberg
Equilibrium in all groups. Genotype counts of individuals
with DM and no DR were compared to patients with each type
of DR. Genotype frequencies for blinding DR are given in
Table 2 and were similar between type 1 and 2 diabetes. No
association was found between any CA SNP and blinding DR
(Table 3), nor the other DR subsets (severe NPDR, PDR, or
CSME, data not shown) in combined DM and for T1DM or
T2DM analyzed independently. The results remained non-
significant  in  the  multivariate  analyses  after  adjusting  for
disease type, sex, duration of disease or HbA1c. A separate
haplotype analysis was undertaken for CA polymorphisms
and  blinding  DR  (Table  4),  NPDR,  PDR,  or  CSME.
Statistically  insignificant  associations  were  found  in  the
combined DM and for separate T1DM and T2DM analyses.
DISCUSSION
The pathogenesis of DR is complex, with few independent
risk  factors  identified  other  than  duration  and  extent  of
hyperglycemia  and  systemic  hypertension.  Increased
carbonic anhydrase levels have been described in the vitreous
of  patients  with  PDR  [23].  Functional  evidence  from  rat
models supports a potential role for CA in the pathogenesis of
DR [23]. It is postulated that CA is released from lysed blood
cells as a result of retinal and vitreous hemorrhage. Increase
of vitreous pH as a result of CA activity is believed to increase
vascular permeability through activation of the kallikrein-
kinin system [23]. This increase in vascular permeability is
likely to result in edema and subsequent damage to the retina,
contributing to DR (and especially macular edema) and vision
loss.  A  pilot  study  of  macular  edema  treatment  with
acetazolamide  showed  significant  improvement  in
fluorescein-angiographic findings and perimetric data, further
TABLE 2. GENOTYPE FREQUENCIES BY TYPE OF DIABETES AND DR STATUS.
T1DM No
DR n (%)
T1DM Blinding
DR n (%)
T2DM No
DR n (%)
T2DM Blinding
DR n (%)
1 rs2403104 TT 48 (53) 36 (57) 78 (43) 60 (47)
TG 34 (37) 21 (33) 88 (48) 54 (42)
GG 9 (10) 6 (10) 16 (9) 15 (12)
2 rs17741410 AA 60 (65) 42 (67) 131 (72) 91 (70)
AG 32 (34) 18 (29) 46 (25) 35 (27)
GG 1 (1) 3 (5) 5 (3) 4 (3)
3 rs1496533 TT 22 (24) 12 (19) 44 (24) 34 (26)
TC 47 (51) 32 (52) 93 (51) 62 (48)
CC 24 (26) 18 (29) 44 (24) 34 (26)
4 rs17814594 TT 58 (65) 45 (73) 131 (72) 89 (70)
TC 30 (34) 15 (24) 46 (25) 36 (28)
CC 1 (1) 2 (3) 4 (2) 3 (2)
5 rs12544332 AA 29 (31) 23 (37) 60 (33) 43 (33)
AC 45 (48) 30 (48) 89 (49) 60 (47)
CC 19 (20) 9 (15) 33 (18) 26 (20)
6 rs1496529 AA 56 (60) 41 (65) 98 (53) 69 (53)
AG 30 (32) 18 (29) 77 (42) 52 (40)
GG 8 (9) 4 (6) 9 (5) 9 (7)
7 rs725605 TT 24 (26) 20 (31) 49 (27) 41 (32)
TC 47 (50) 31 (48) 93 (51) 62 (48)
CC 23 (24) 13 (20) 40 (22) 27 (21)
8 rs2645050 AA 60 (65) 44 (71) 131 (72) 90 (70)
AG 32 (34) 16 (26) 45 (25) 36 (28)
GG 1 (1) 2 (3) 5 (3) 3 (2)
9 rs2645049 CC 54 (58) 37 (59) 93 (51) 70 (54)
CT 27 (29) 19 (30) 80 (44) 51 (40)
TT 12 (13) 7 (11) 9 (5) 8 (6)
10 rs13278559 CC 78 (84) 54 (86) 147 (81) 105 (81)
CT 15 (16) 8 (13) 33 (18) 24 (18)
TT 0 (0) 1 (2) 2 (1) 1 (1)
Results are presented as n (%).
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SNP                          Genotypesupporting the role of carbonic anhydrase in DR development
[29]. In these functional studies, proteins have been assayed
at a late time point in the disease process, as vitreous was
removed from patients during vitrectomy as a treatment for
advanced disease. In addition, the role of CA in these studies
has been associated with sight threatening DR. It is therefore
possible that CA is involved only in end stage damage to the
retina, such as that of PDR and CSME and not in NPDR. Thus
it is difficult to know if the CA in vitreous increases as a cause
or consequence of DR.
To our knowledge, this is the first report investigating CA
sequence variation as a risk factor for DR. Our results suggest
that common sequence variation in CA is not a major risk
factor for the development of DR in either T1DM or T2DM.
It is acknowledged that participants with DR had the presence
of increased risk factors (including older age, longer diabetes
duration,  higher  HbA1c  levels,  and  higher  rates  of
nephropathy) when compared to those without DR. However
an attempt to control for their effects on DR development was
made  in  the  multivariate  analyses.  While  this  study  was
powered to detect a modest effect size odds ratio (OR=1.5),
the study design does not allow us to exclude a rare  CA
polymorphism, or a series of separate uncommon pathogenic
mutations as a contributor to DR development in a small
subset of DR subjects. It is also possible that other factors,
perhaps different genetic loci, may play a role in the regulation
of CA. It remains to be determined by clinical studies whether
CA represents a valid target for the treatment or prevention of
DR.
Further  research  is  required  to  obtain  a  better
understanding of DR pathogenesis and to decrease this global
burden of disease.
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TABLE 3. P-VALUES FOR ASSOCIATION OF CA TAG SNPS WITH BLINDING DR BY TYPE OF DIABETES UNDER DOMINANT AND RECESSIVE GENETIC
MODELS.
Combined DM                                          T1DM                                                 T2DM
Dominant               Recessive             Dominant              Recessive Dominant Recessive
rs2403104 0.46 0.31 0.73 0.92 0.54 0.36
rs17741410 0.74 0.79 0.99 0.54 0.70 0.89
rs1496533 0.77 0.75 0.68 0.93 0.85 0.85
rs17814594 0.83 0.91 0.74 0.80 0.65 0.99
rs12544332 0.87 0.73 0.48 0.44 0.82 0.94
rs1496529 0.82 0.99 0.36 0.60 0.74 0.80
rs725605 0.23 0.68 0.51 0.33 0.26 0.98
rs2645050 0.93 0.98 0.95 0.76 0.92 0.85
rs2645049 0.83 0.78 0.87 0.45 0.93 0.84
rs13278559 0.84 0.45 0.51 0.23 0.55 0.89
Results have been adjusted for sex, diabetes type, duration of disease, and HbA1c.
TABLE 4. FREQUENCY OF COMMON HAPLOTYPES AND ASSOCIATION WITH BLINDING DR UNDER ADDITIVE AND DOMINANT GENETIC MODELS.
T1DM
Haplotype
frequency
No DR
frequency
Blinding DR
frequency
Additive
 p value
Dominant
 p value
1 T G T CCA C G C C 0.165 0.175 0.151 0.404 0.333
2 GATTC G C A T C 0.205 0.218 0.184 0.429 0.616
3 T A C T AAT A C C 0.428 0.410 0.459 0.203 0.228
T2DM Haplotype
frequency
No DR
frequency
Blinding DR
frequency
Additive
 p value
Dominant
 p value
1 GATTAAT A C T 0.041 0.045 0.034 0.822 0.818
2 T A C T AAT A C T 0.050 0.046 0.051 0.504 0.502
3 T G T CCA C G C C 0.151 0.143 0.162 0.556 0.466
4 GATTC G C A T C 0.224 0.220 0.229 0.516 0.540
5 T A C T AAT A C C 0.397 0.392 0.410 0.863 0.941
SNPs are numbered as in Table 2 and the p-value for all haplotypes with a frequency >2% are given. Results have been adjusted
for sex, diabetes type, duration of disease and HbA 1c.
Molecular Vision 2009; 15:1179-1184 <http://www.molvis.org/molvis/v15/a125> © 2009 Molecular Vision
1182
Haplotype 123456789 10
Haplotype 123456789 10
SNPFlinders  Medical  Research  Foundation  provided  financial
assistance.
REFERENCES
1. Wild S, Roglic G, Green A, Sicree R, King H. Global prevalence
of diabetes: estimates for the year 2000 and projections for
2030. Diabetes Care 2004; 27:1047-53. [PMID: 15111519]
2. Kempen JH, O'Colmain BJ, Leske MC, Haffner SM, Klein R,
Moss SE, Taylor HR, Hamman RF, Eye Diseases Prevalence
Research  Group.  The  prevalence  of  diabetic  retinopathy
among adults in the United States. Arch Ophthalmol 2004;
122:552-63. [PMID: 15078674]
3. Saaddine JB, Honeycutt AA, Narayan KM, Zhang X, Klein R,
Boyle JP. Projection of diabetic retinopathy and other major
eye diseases among people with diabetes mellitus: United
States,  2005–2050.  Arch  Ophthalmol  2008;  126:1740-7.
[PMID: 19064858]
4. Stratton IM, Adler AI, Neil HA, Matthews DR, Manley SE, Cull
CA,  Hadden  D,  Turner  RC,  Holman  RR.  Association  of
glycaemia  with  macrovascular  and  microvascular
complications of type 2 diabetes (UKPDS 35): prospective
observational  study.  BMJ  2000;  321:405-12.  [PMID:
10938048]
5. The relationship of glycemic exposure (HbA1c) to the risk of
development and progression of retinopathy in the diabetes
control and complications trial. Diabetes 1995; 44:968-83.
[PMID: 7622004]
6. Klein R, Klein BE, Moss SE, Davis MD, DeMets DL. The
Wisconsin epidemiologic study of diabetic retinopathy. III.
Prevalence  and  risk  of  diabetic  retinopathy  when  age  at
diagnosis  is  30  or  more  years.  Arch  Ophthalmol  1984;
102:527-32. [PMID: 6367725]
7. Klein R, Klein BE, Moss SE, Davis MD, DeMets DL. The
Wisconsin epidemiologic study of diabetic retinopathy. II.
Prevalence  and  risk  of  diabetic  retinopathy  when  age  at
diagnosis  is  less  than  30  years.  Arch  Ophthalmol  1984;
102:520-6. [PMID: 6367724]
8. Mitchell  P.  Development  and  progression  of  diabetic  eye
disease in Newcastle (1977–1984): rates and risk factors. Aust
N Z J Ophthalmol 1985; 13:39-44. [PMID: 4015877]
9. Jerneld B, Algvere P. Relationship of duration and onset of
diabetes  to  prevalence  of  diabetic  retinopathy.  Am  J
Ophthalmol 1986; 102:431-7. [PMID: 3766657]
10. Tight blood pressure control and risk of macrovascular and
microvascular complications in type 2 diabetes: UKPDS 38.
UK  Prospective  Diabetes  Study  Group.  BMJ  1998;
317:703-13. [PMID: 9732337]
11. Hallman DM, Huber JC Jr, Gonzalez VH, Klein BE, Klein R,
Hanis  CL.  Familial  aggregation  of  severity  of  diabetic
retinopathy in Mexican Americans from Starr County, Texas.
Diabetes Care 2005; 28:1163-8. [PMID: 15855583]
12. Clustering of long-term complications in families with diabetes
in the diabetes control and complications trial. The Diabetes
Control and Complications Trial Research Group. Diabetes
1997; 46:1829-39. [PMID: 9356033]
13. Monti MC, Lonsdale JT, Montomoli C, Montross R, Schlag E,
Greenberg  DA.  Familial  risk  factors  for  microvascular
complications and differential male-female risk in a large
cohort of American families with type 1 diabetes. J Clin
Endocrinol Metab 2007; 92:4650-5. [PMID: 17878250]
14. Hietala K, Forsblom C, Summanen P, Groop PH. Heritability
of  proliferative  diabetic  retinopathy.  Diabetes  2008;
57:2176-80. [PMID: 18443200]
15. Nakanishi T, Koyama R, Ikeda T, Shimizu A. Catalogue of
soluble proteins in the human vitreous humor: comparison
between diabetic retinopathy and macular hole. J Chromatogr
B  Analyt  Technol  Biomed  Life  Sci  2002;  776:89-100.
[PMID: 12127329]
16. Yamane  K,  Minamoto  A,  Yamashita  H,  Takamura  H,
Miyamoto-Myoken Y, Yoshizato K, Nabetani T, Tsugita A,
Mishima HK. Proteome analysis of human vitreous proteins.
Mol Cell Proteomics 2003; 2:1177-87. [PMID: 12975481]
17. Inomata Y, Hirata A, Takahashi E, Kawaji T, Fukushima M,
Tanihara H. Elevated erythropoietin in vitreous with ischemic
retinal  diseases.  Neuroreport  2004;  15:877-9.  [PMID:
15073535]
18. Watanabe D, Suzuma K, Matsui S, Kurimoto M, Kiryu J, Kita
M, Suzuma I, Ohashi H, Ojima T, Murakami T, Kobayashi
T,  Masuda  S,  Nagao  M,  Yoshimura  N,  Takagi  H.
Erythropoietin as a retinal angiogenic factor in proliferative
diabetic  retinopathy.  N  Engl  J  Med  2005;  353:782-92.
[PMID: 16120858]
19. Katsura Y, Okano T, Matsuno K, Osako M, Kure M, Watanabe
T, Iwaki Y, Noritake M, Kosano H, Nishigori H, Matsuoka
T.  Erythropoietin  is  highly  elevated  in  vitreous  fluid  of
patients with proliferative diabetic retinopathy. Diabetes Care
2005; 28:2252-4. [PMID: 16123502]
20. Henry RP. Multiple roles of carbonic anhydrase in cellular
transport  and  metabolism.  Annu  Rev  Physiol  1996;
58:523-38. [PMID: 8815807]
21. Wistrand  PJ,  Schenholm  M,  Lonnerholm  G.  Carbonic
anhydrase isoenzymes CA I and CA II in the human eye.
Invest  Ophthalmol  Vis  Sci  1986;  27:419-28.  [PMID:
3081459]
22. Wolfensberger TJ, Mahieu I, Jarvis-Evans J, Boulton M, Carter
ND, Nógrádi A, Hollande E, Bird AC. Membrane-bound
carbonic  anhydrase  in  human  retinal  pigment  epithelium.
Invest  Ophthalmol  Vis  Sci  1994;  35:3401-7.  [PMID:
8056514]
23. Gao  BB,  Clermont  A,  Rook  S,  Fonda  SJ,  Srinivasan  VJ,
Wojtkowski M, Fujimoto JG, Avery RL, Arrigg PG, Bursell
SE, Aiello LP, Feener EP. Extracellular carbonic anhydrase
mediates  hemorrhagic  retinal  and  cerebral  vascular
permeability through prekallikrein activation. Nat Med 2007;
13:181-8. [PMID: 17259996]
24. Grading diabetic retinopathy from stereoscopic color fundus
photographs–an  extension  of  the  modified  Airlie  House
classification. ETDRS report number 10. Early Treatment
Diabetic Retinopathy Study Research Group. Ophthalmology
1991; 98:786-806. [PMID: 2062513]
25. Barrett JC, Fry B, Maller J, Daly MJ. Haploview: analysis and
visualization  of  LD  and  haplotype  maps.  Bioinformatics
2005; 21:263-5. [PMID: 15297300]
26. The International HapMap Project. Nature 2003; 426:789-96.
[PMID: 14685227]
27. Sole X, Guino E, Valls J, Iniesta R, Moreno V. SNPStats: a web
tool for the analysis of association studies. Bioinformatics
2006; 22:1928-9. [PMID: 16720584]
28. Schaid DJ, Rowland CM, Tines DE, Jacobson RM, Poland GA.
Score tests for association between traits and haplotypes when
Molecular Vision 2009; 15:1179-1184 <http://www.molvis.org/molvis/v15/a125> © 2009 Molecular Vision
1183linkage  phase  is  ambiguous.  Am  J  Hum  Genet  2002;
70:425-34. [PMID: 11791212]
29. Giusti C, Forte R, Vingolo EM, Gargiulo P. Is acetazolamide
effective in the treatment of diabetic macular edema? A pilot
study. Int Ophthalmol 2001; 24:79-88. [PMID: 12201348]
Molecular Vision 2009; 15:1179-1184 <http://www.molvis.org/molvis/v15/a125> © 2009 Molecular Vision
The print version of this article was created on 10 June 2009. This reflects all typographical corrections and errata to the article
through that date. Details of any changes may be found in the online version of the article.
1184